Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty

Cornea

Volumn 27, Issue 4, 2008, Pages 488-493

  Dhaliwal, Jasmeet S ^a   Mason, Benjamin F ^a   Kaufman, Stephen C ^a,b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cornea; FK506; Graft; Keratoplasty; Protopic; Tacrolimus

Indexed keywords

BACQUACIL; BRIMONIDINE; CYCLOSPORIN A; GRAMICIDIN; LOTEPREDNOL ETABONATE; NEOMYCIN; NEOSPORIN; POLY(HEXAMETHYLENEBIGUANIDE); POLYMYXIN B; PREDNISOLONE ACETATE; PREDNISONE; TACROLIMUS; TIMOLOL; TRIFLURIDINE; VALACICLOVIR;

ABSENCE OF SIDE EFFECTS; ACANTHAMOEBA KERATITIS; ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; CATARACT; CHRONIC DRUG ADMINISTRATION; CONGENITAL CORNEA DYSTROPHY; CORNEA TRANSPLANTATION; CORNEA ULCER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE EPITHELIUM TOXICITY; EYE TOXICITY; FEMALE; FOLLOW UP; GLAUCOMA; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR PRESSURE; KERATOCONUS; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS REACTIVATION;

ADMINISTRATION, TOPICAL; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; OINTMENTS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 42549169600     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181606086     Document Type: Article

References (37)

1. Reis A, Reinhard T, Sundmacher R, et al. A comparative investigation of FK506 and cyclosporine A in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol. 1998;236:785-789.
2. Eye Bank Association of America. 2006 Eye Bank Association of America Statistical Report, Washington, DC: Eye Bank Association of America.
3. The Collaborative Corneal Transplantation Studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992;110:1392-1403.
4. Hill JC. Systemic cyclosporine in high-risk keratoplasty: short- versus long-term therapy. Ophthalmology. 1994;101:128-133.
5. Hill JC. Immunosuppression in corneal transplantation. Eye. 1995;9:247-253.
6. Fine M, Stein M. The role of corneal vascularization in human corneal graft reactions. In: Ruth P, Knight J, eds. Corneal Graft Failure. Amsterdam: Elsevier; 1973;193-204.
7. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies. Ophthalmology. 1994;101:1536-1547.
8. Belin MW, Bouchard CS, Franz S, et al. Topical cyclosporine in high-risk corneal transplants. Ophthalmology. 1989;96:1144-1150.
9. Foets B, Missotten L, Vanderveeren P, et al. Prolonged survival of allogenic grafts in rabbits treated with topically applied cyclosporin A; systemic absorption and local immunosuppressive effect. Br J Ophthalmol. 1985;69:600-603.
10. Hunter PA, Garner A, Wilhelmus KR, et al. Corneal graft rejection: a new rabbit model and cyclosporine-A. Br J Ophthalmol. 1982;66:292-302.
11. Coster DJ, Shepherd WFI, Chin Fook T, et al. Prolonged survival of corneal allografts in rabbits treated with cyclosporine A. Lancet. 1979;2:688-689.
12. Bell TG, Easy DL, McCullagh KG. A placebo-controlled blind trial of cyclosporine-A in prevention of corneal graft rejection in rabbits. Br J Ophthalmol. 1982;66:303-308.
13. Shepherd WI, Coster DJ, Chin Fook T, et al. Effect of cyclosporine A on the survival of corneal grafts in rabbits. Br J Ophthalmol. 1980;64:148-153.
14. Hill JC, Maske R. An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation. 1988;46:26-30.
15. Sloper CM, Powell RJ, Dua H. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 2001;108:1838-1844.
16. Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ. 1999;318:1104-1107.
17. Cespo-Leiro MG. Tacrolimus in heart transplantation. Transplant Proc. 2003;35:1981-1983.
18. Bhorade SM, Jordan A, Villanueva L, et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. Am J Transplant. 2003;3:1570-1575.
19. Celli S, Valdivia J, Fung J, et al. Long-term survival of heart and liver xenografts with splenectomy and FK-506. Transplant Proc. 1993;25:647-648.
20. Hikita N, Lopez J, Chan C, et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci. 1997;38:901-909.
21. Khodadoust AA. The allograft rejection reaction: the leading cause of late failure of clinical corneal grafts. In: Ruth P, Knight J, eds. Corneal Graft Failure. Amsterdam: Elsevier; 1973:151-167.
22. Price M, Price F. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology. 2006;113:1785-1790.
23. Akiyama S. Local administration of cyclosporine and FK-506 for suppression of corneal graft rejection: a comparative study. Folia Ophthalmol Jpn. 1992;43:583-587.
24. Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea. 2005;24:417-420.
25. Mills RA, Jones DB, Winkler CR, et al. Topical FK-506 prevents experimental corneal allograft rejection. Cornea. 1995;14:157-160.
26. Starzl TE, Murase N, Demetris AJ, et al. Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment. Ann N Y Acad Sci. 1993;685:46-51.
27. Nishi M, Herbort C, Matsubara M, et al. Effect of the immunosuppressant FK-506 on a penetrating keratoplasty rejection model in the rat. Invest Ophthalmol Vis Sci. 1993;34:2477-2486.
28. Kobayashi C, Kanai A, Nakajima A, et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK506. Transplant Proc. 1989;21:3156-3158.
29. Benelli U, Lepri A, Del Tacca M, et al. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther. 1996;12:425-431.
30. Benelli U, Ross JR, Nardi M, et al. Corneal neovascularization induced by xenografts or chemical cautery: inhibition by cyclosporin A. Invest Ophthalmol Vis Sci. 1997;38:274-282.
31. Stumpf T, Luqmani N, Sumich P, et al. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25:1147-1149.
32. Pleyer U, Lutz S, Jusko W, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulation in the rabbit eye. Invest Ophthalmol Vis Sci. 1993;34:2737-2742.
33. Tuft SJ, Kemeny DM, Dart JK, et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology. 1991;98:150-158.
34. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994;118:723-729.
35. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115:763-769.
36. Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114:1000-1006.
37. Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol. 2007;17:69-74.